{"abstract": "Pfizer will take a charge of $2.8 billion for costs associated with Exubera, making it one of the most expensive flops in the history of the pharmaceutical industry.", "web_url": "https://www.nytimes.com/2007/10/18/business/18cnd-exubera.html", "snippet": "Pfizer will take a charge of $2.8 billion for costs associated with Exubera, making it one of the most expensive flops in the history of the pharmaceutical industry.", "lead_paragraph": "Pfizer said today that it would stop selling Exubera, its inhaled insulin, less than two years after introducing the drug. Despite Pfizer\u2019s heavy promotion, Exubera\u2019s sales had been miniscule, with prescriptions amounting to less than 1 percent of the insulin market. ", "source": "The New York Times", "multimedia": [], "headline": {"main": "Weak Sales Prompt Pfizer to Cancel Diabetes Drug", "kicker": null, "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Pfizer Inc", "rank": 1, "major": "N"}, {"name": "subject", "value": "Exubera (Drug)", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Insulin", "rank": 4, "major": "N"}], "pub_date": "2007-10-18T04:00:00+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Alex Berenson", "person": [{"firstname": "Alex", "middlename": null, "lastname": "Berenson", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/7e908ab2-a313-55f2-9383-85d41b0254e2", "word_count": 984, "uri": "nyt://article/7e908ab2-a313-55f2-9383-85d41b0254e2"}